ADVERTISEMENT

ADVERTISEMENT

ALDEVRON

John Ballantyne, who co-founded Aldevron in 1998, has departed the biotechnology firm after it was acquired for $9.6 billion by Danaher Corp., believed to be the biggest business acquisition in North Dakota history.
The purchase will allow Aldevron to take "next steps" and to bring new genomic therapies and vaccines to market faster, according to an announcement of the deal.
Behind the scenes, Aldevron has produced custom DNA to make millions of doses of vaccine to protect against the coronavirus. It is announcing expanded collaboration with Moderna, a leading manufacturer of a coronavirus vaccine that uses messenger RNA, also known as mRNA.
Genovac, recently spun off from Aldevron, has clients in North America, Europe, Australia and Asia. The firm has technology that enables rapid antibody screening and development of drugs to fight infectious diseases, including COVID-19.

ADVERTISEMENT

Latest Headlines
Agathos Biologics, a biotechnology startup in Fargo, is working to develop cell lines to develop vaccines and other drugs that are not derived from sources that pose ethical dilemmas, such as cells from aborted fetuses.
Biomed Protection has an online analytical tool to evaluate a vaccine's effectiveness against coronavirus mutations, which could help vaccine makers respond to the rapidly changing virus. The firm also is testing some of its own vaccine candidates that could be developed in North Dakota.
The library foundation announced on Thursday, Jan. 28, that former pharmaceutical executive Victoria Chambers, nonprofit boss Eric Jolly and retired law firm partner Vaughn Williams have joined the 12-member board of trustees.
Regenxbio, a Maryland company, contends that Aldevron is violating a patent it holds for making materials to deliver gene therapies to target cells in patients. An Aldevron spokeswoman said the company respects intellectual property and the company is confident a judge will find that it has not infringed on the patent.
Fargo startup will use innovative technology to track coronavirus mutations and develop vaccine candidates that could start production here in December in partnership with Aldevron.
The new CEO will allow founder Michael Chambers to assume the role of executive chairman as the firm charts its course during a time of rapid growth. In three years, the campus will employ 1,000, with expectations of further growth ahead.

ADVERTISEMENT

FARGO — Aldevron is supplying plasmid DNA to a research team that is on the cutting edge of developing a coronavirus vaccine.
FARGO — A Fargo biotechnology company will manufacture genetic material for an experimental vaccine to protect against infection from the coronavirus in a partnership with researchers at Massachusetts General Hospital.
FARGO — North Dakota State University donors gave more than $160 million last year, topping the previous record by more than twofold.

ADVERTISEMENT

ADVERTISEMENT